Antibiotic resistance exposes gaps across healthcare, farming and drug production
Published on 20 October 2026 at 03:53 GMT
By Editorial Team SDG3
Antibiotic resistance is testing more than the ability of laboratories to discover medicines. The systems that prescribe, produce and dispose of antibiotics also influence how long treatments remain effective. Across hospitals, livestock production and waterways, resistance connects decisions usually managed by separate institutions. A new medicine enters this existing network of infection, antibiotic exposure and environmental contamination.
Antibiotics treat bacterial infections; antimicrobial resistance also encompasses resistance in viruses, fungi and parasites to their respective medicines. The problem does not mean every antibiotic has stopped working. It means treatment options depend increasingly on which organism is causing an infection and which medicines remain active against it. The consequences include more difficult treatment and additional pressure on health services.
The World Health Organization (WHO) identifies both inappropriate antibiotic use and restricted access to appropriate diagnostics, vaccines and medicines as drivers of the crisis. Poor infection prevention in households, healthcare facilities and farms adds to that pressure. These connections place resistance within SDG 3 (Good health and well-being): treatment depends partly on preventing infections and making suitable care available.
Prescribing depends on information
Antimicrobial stewardship concerns the appropriate selection and use of treatment against an identified or suspected infection. A lower prescription total alone does not establish whether patients received appropriate care. WHO's global action plan links appropriate antimicrobial use with equitable access, alongside measures to prevent infections.
Diagnostic information helps distinguish different treatment questions: whether an infection is bacterial, which bacterium is present, and whether it is susceptible to an antibiotic. Those are different capabilities. A technology that identifies a pathogen does not necessarily answer every question about resistance or provide a result usable in every clinical setting.
In its October 2025 assessment, WHO reported limited simple diagnostic tools for primary and secondary care, alongside gaps in tests for bloodstream infections and insufficient access to biomarkers that help distinguish bacterial from viral infections. It called for affordable, robust platforms suited to settings with limited resources. The assessment connects diagnostic innovation to the facilities where patients first seek care.
WHO identifies diagnostic innovation and equitable access as parts of the response alongside drug discovery and clinical development. Identifying an infection and determining susceptibility can inform treatment selection, but the availability of a new medicine does not itself provide those diagnostic capabilities.
Resistance beyond the clinic
The United Nations Environment Programme (UNEP) examines resistance through a One Health approach connecting people, animals, plants and ecosystems. Its report, Bracing for Superbugs, identifies pharmaceuticals and chemicals, agriculture and food, and healthcare as interconnected sources of environmental pressure, alongside municipal sewage and poor sanitation.
Livestock production belongs in that picture because antibiotic use and animal waste connect farming with the wider environment. Healthcare facilities and households also contribute waste streams. These pathways complicate attempts to assign the problem exclusively to individual prescribing decisions. Reducing exposure in one setting does not describe what is happening across the rest of the system.
Sanitation concerns both the prevention of infection and the management of contaminated waste. UNEP calls for action across these sectors while identifying gaps in knowledge about their environmental contributions. Its assessment does not establish a precise global share of human resistant infections attributable to particular farms, factories or waterways.
Manufacturing introduces a separate contradiction. Antibiotic production supplies treatment, yet releases from that production can contribute to resistance. In guidance published in September 2024, WHO reported widely documented high antibiotic levels downstream of manufacturing sites and described manufacturing pollution as largely unregulated. It also noted that medicine quality assurance criteria typically do not address environmental emissions.
The guidance provides a scientific basis for discharge targets and sets out risk management, auditing and transparency practices. It recognises the importance of progressive implementation alongside affordable access and security of supply. A medicine's quality as a finished product and the environmental conditions under which it was produced are therefore separate questions for purchasers and regulators.
Paying for availability rather than volume
The development pipeline presents another constraint. WHO reported 90 antibacterial agents in clinical development in its 2025 assessment, compared with 97 in 2023. The newer total included 50 traditional agents and 40 non-traditional approaches. Those categories include different technologies; the headline number is not a count of newly approved antibiotics available to patients.
The House of Commons Library describes a commercial tension behind antibiotic development: research requires substantial investment, while limiting use can reduce the sales available to recover that investment. A medicine may have value to a health system as an available treatment even when it is prescribed infrequently.
NHS England has developed an antimicrobial subscription model to address that mismatch. As described by the House of Commons Library, it provides fixed annual fees for access to selected antibiotics. The National Institute for Health and Care Excellence assesses eligibility and value to the NHS, which informs the level of payment. The model aims to encourage development without rewarding higher use.
A subscription changes the payment incentive; diagnostic services and wastewater management remain separate parts of the response. The model recognises value that sales volumes can miss. Whether similar arrangements can sustain development and access across different health systems remains an open question.
The policies address different stages of antibiotic development, use and disposal. WHO links innovation with diagnostic access and infection prevention, while UNEP identifies environmental releases as another part of the response. Subscription payments address the commercial problem of financing medicines whose use is deliberately limited; their wider contribution depends on the products and access they support.
Written by a human author, edited with AI assistance.
Further information:
• World Health Organization, its July 2026 fact sheet explains resistance, health-system impacts, access barriers and infection prevention.
• World Health Organization, its October 2025 update presents antibacterial pipeline findings and diagnostic gaps, with links to both original reports.
• United Nations Environment Programme, Bracing for Superbugs examines environmental pathways across healthcare, food production, pharmaceuticals and sanitation.
• World Health Organization, its 2024 manufacturing guidance explains pollution risks, discharge targets and implementation considerations.
• House of Commons Library, its September 2024 briefing explains the rationale for subscription payments and how eligibility and value are assessed.
